

Week 13 - Week Ending Mar 30, 2024


For the week ending Mar 30, 2183 respiratory patient specimens were submitted for Influenza A/B and Respiratory Syncytial Virus (RSV) testing.


Influenza A was detected in 127 of 2183 specimens (5.8%). Influenza B was detected in 186 of 2183 specimens (8.52%). RSV was detected in 13 of 2183 specimens (0.6%).





Week 13 - Week Ending Mar 30, 2024







Week 13 - Week Ending Mar 30, 2024

For the week ending Mar 30, 2463 respiratory patient specimen were submitted for COVID-19 testing.


SARS-CoV-2 was detected in 100 of 2463 specimens (4.1%).






Week 13 - Week Ending Mar 30, 2024

For the week ending Mar 30, 86 respiratory patient specimens were submitted for Human Metapneumovirus (hMPV),
Adenovirus (AdV), & Rhinovirus (RV) testing.
hMPV was detected in 6 of 86 specimens (7%).
AdV was detected in 1 of 86 specimens (1.2%).
RV was detected in 14 of 86 specimens (16.3%).





Week 13 - Week Ending Mar 30, 2024

For the week ending Mar 30, 68 respiratory patient specimens were submitted for Parainfluenza (PIV) testing.

PIV1 was detected in 0 of 68 specimens (0%). PIV2 was detected in 0 of 68 specimens (0%). PIV3 was detected in 0 of 68 specimens (0%). PIV4 was detected in 0 of 68 specimens (0%).

